Zydus and Formycon advance FYB206, the first publicly announced Keytruda biosimilar accepted for FDA review, with a decision anticipated in Q3 2027.
Written By: Khushi Patel, PharmD
Reviewed By: Pharmacally Editorial Team
Zydus Lifesciences and Formycon AG announced on October 13, 2026, that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda (pembrolizumab). According to the companies, this is the first publicly announced FDA acceptance of an application for a proposed Keytruda biosimilar, to the best of their knowledge.
Submitted in the third quarter of 2026, the application is expected to receive a regulatory decision in the third quarter of 2027, based on the companies stated review timeline. The regulatory dossier has also been submitted to Health Canada, extending the programme’s regulatory progress beyond the United States.
Dahlia Study Supports the Biosimilar Development Strategy
The pivotal Dahlia pharmacokinetic (PK) study met its primary objective in February 2026, demonstrating pharmacokinetic equivalence between FYB206 and reference pembrolizumab. The randomized, double-blind, multicentre study provided clinical evidence supporting the biosimilar development programme.
The study formed part of a streamlined clinical strategy agreed upon with the FDA in early 2025. Rather than conducting a comparative Phase III efficacy trial, Formycon pursued a development package built around comprehensive analytical and functional comparability data alongside the Dahlia PK study. Clinical development was completed in July 2026.
This approach reflects a broader regulatory shift towards greater reliance on analytical evidence when establishing biosimilarity. In draft guidance issued in October 2025, the FDA proposed that comparative efficacy studies would generally no longer be necessary for therapeutic protein biosimilars when sufficient evidence can be obtained through other elements of the comparability assessment.
The acceptance of FYB206’s BLA indicates that the application has progressed into formal regulatory review. It does not, however, establish that the FDA has concluded its assessment of biosimilarity, safety, effectiveness or manufacturing quality.
Zydus and Formycon Divide Development and Commercial Responsibilities
Formycon and Zydus entered into an exclusive licensing and supply agreement for FYB206 in December 2025, covering the United States and Canada.
Under the agreement, Formycon is responsible for completing development, preparing and filing regulatory dossiers, and supplying the product. Zydus holds the exclusive commercialisation rights in the two markets, subject to regulatory approval and resolution of intellectual property issues.
The FDA’s acceptance of the BLA also triggers a contractual regulatory milestone entitling Formycon to a payment from Zydus. Formycon retains global rights to FYB206 and is entitled to participate in the gross profits generated by its commercialisation partners.
The companies’ strategy combines Formycon’s biosimilar development capabilities with Zydus’s commercial infrastructure in North America. However, commercialisation timing will depend on the regulatory outcome and applicable intellectual property considerations.
Keytruda’s Market Position Raises the Commercial Stakes
Pembrolizumab is an immune checkpoint inhibitor that blocks the programmed cell death protein 1 (PD-1) receptor, helping restore antitumour immune activity. It is used across multiple cancer indications, including several solid tumours and haematological malignancies.
Keytruda, including its subcutaneous formulation Keytruda Qlex, generated worldwide sales of $31.7 billion in 2025. Combined sales reached $16.4 billion in the first half of 2026, according to Formycon.
These sales figures illustrate the commercial significance of developing a biosimilar to pembrolizumab. Nevertheless, FYB206’s eventual market position will depend on regulatory approval, intellectual property considerations, commercial execution and competition from other biosimilar developers.
Regulatory Review Marks a Key Development Milestone
FYB206’s entry into FDA review advances the programme beyond clinical development and into a critical regulatory phase. The absence of a comparative Phase III efficacy trial may have reduced development time and investment requirements, while the analytical and pharmacokinetic evidence remains central to the biosimilarity assessment.
With a decision anticipated in the third quarter of 2027 and a dossier submitted to Health Canada, the programme is progressing towards potential entry into two major North American markets. Whether FYB206 can translate this regulatory progress into commercial availability will depend on the outcome of the ongoing reviews and the resolution of remaining market-entry requirements.
Reference
Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA, Zydus LifeScience, 13 October 2026
About the Writer
Khushi Patel is a Pharm.D (Linkedin) professional with a strong foundation in clinical pharmacy, patient-centered care, regulatory affairs, and pharmacovigilance, with published work on Brugada syndrome.
Her interests include regulatory affairs, pharmacovigilance, guideline integration, multimodal therapy, pharmacogenomics, and antibiogram utilization, with a focus on evidence-based clinical decision-making and medication safety.
As a Pharmacally healthcare writer, she translates clinical and scientific evidence into clear, accurate, and clinically relevant healthcare content, while continuously developing her expertise in evolving pharmacy practice.